Body Mass Index and the Success of Helicobacter-pylori Eradication Therapy

  Helicobacter pylorus (H. pylori) is a gram-negative spiral bacterium related to varieties of gastric and extra-gastric complications. The effects of H. pylori infection on cardiometabolic conditions such as dyslipidemia, diabetes, and metabolic syndrome have to need to be investigated. The present paper aims to assess the effects of body mass index on the success of helicobacter-pylori eradication therapy for the first time.

  This study included 198 patients with H. pylori infection. Patients underwent H. pylori eradication using clarithromycin (500 mg, twice daily, pantoprazole (40 mg, twice daily), amoxicillin (500 mg, three times daily), and bismuth substrate (120 mg, twice daily) for 14 days. After that, the success of eradication was assessed through stool antigen within a month following the treatment. The association of eradication success with age, gender, and BMI were evaluated. 

 H. pylori infection was eradicated in 76.3% (P-value<0.001) of the patients following the eradicative treatment. The rate of response to the anti-H. Pylori remedy was affected by age (P-value=0.29). But it wasn’t affected by gender (P-value=0.81), and BMI (P-value=0.60).

 Based on the findings of this study, the patientschr('39') response to the H. Pylori eradication was not affected by age, gender, and BMI.